{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T15:36:01Z","timestamp":1793028961774,"version":"4.5.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100013373","name":"NIHR Oxford Biomedical Research Centre","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013373","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13643-017-0636-y","type":"journal-article","created":{"date-parts":[[2017,12,6]],"date-time":"2017-12-06T01:49:33Z","timestamp":1512524973000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Non-conventional dosing of oral anticancer agents in oncology and malignant haematology: a systematic review protocol"],"prefix":"10.1186","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9578-7632","authenticated-orcid":false,"given":"Faouzi","family":"Djebbari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Stoner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verna","family":"Lavender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,6]]},"reference":[{"issue":"2","key":"636_CR1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.molonc.2012.02.004","volume":"6","author":"S Hoelder","year":"2012","unstructured":"Hoelder S, et al. Discovery of small molecule cancer drugs: Successes, challenges and opportunities. Mol Oncol. 2012;6(2):155\u201376. doi: 10.1016\/j.molonc.2012.02.004 .","journal-title":"Mol Oncol"},{"key":"636_CR2","volume-title":"British National Formulary","author":"British Medical Association, Royal Pharmaceutical Society","year":"2017","unstructured":"British Medical Association, Royal Pharmaceutical Society. British National Formulary. 73rd ed. London: BMJ group and Pharmaceutical Press; 2017.","edition":"73"},{"issue":"4","key":"636_CR3","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1586\/14737140.2016.1159515","volume":"16","author":"WC Huang","year":"2016","unstructured":"Huang WC, et al. Medication adherence to oral anticancer drugs: systematic review. Expert Rev Anticancer Ther. 2016;16(4):423\u201332. doi: 10.1586\/14737140.2016.1159515 .","journal-title":"Expert Rev Anticancer Ther"},{"key":"636_CR4","doi-asserted-by":"crossref","unstructured":"Patridge A et al. Adherence to Therapy With Oral Antineoplastic Agents. Journal of the National Cancer Institute. 2002; 94(9): 652-661. Available from: https:\/\/academic.oup.com\/jnci\/article\/94\/9\/652\/2520164\/Adherence-to-Therapy-With-Oral-Antineoplastic . Accessed 25 Nov 2017.","DOI":"10.1093\/jnci\/94.9.652"},{"key":"636_CR5","unstructured":"European Organisation for Research and Treatment of Cancer. Quality of Life. Available from: http:\/\/groups.eortc.be\/qol\/ . Accessed 25 Nov 2017."},{"key":"636_CR6","unstructured":"Electronic Medicines Compendium. Summary of Product Characteristics: Zelboraf 240 mg Film-coated Tablets. Available from: http:\/\/www.medicines.org.uk\/emc\/medicine\/26056 . Accessed 25 Nov 2017."},{"issue":"2","key":"636_CR7","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347. doi: 10.1016\/j.ejca.2008.10.026 .","journal-title":"Eur J Cancer"},{"issue":"8","key":"636_CR8","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):328\u201346.","journal-title":"Lancet Oncol"},{"key":"636_CR9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.","journal-title":"Syst Rev"},{"issue":"2","key":"636_CR10","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1471-1842.2009.00848.x","volume":"26","author":"MJ Grant","year":"2009","unstructured":"Grant MJ, Booth A. A typology of reviews: an analysis of 14 review types and associated methodologies. Health Inf Libr J. 2009;26(2):91\u2013108. doi: 10.1111\/j.1471-1842.2009.00848.x .","journal-title":"Health Inf Libr J"},{"issue":"9","key":"636_CR11","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1517\/14656566.6.9.1463","volume":"6","author":"KK Jain","year":"2005","unstructured":"Jain KK. Personalised medicine for cancer: from drug development into clinical practice. Expert Opin Pharmacother. 2005;6(9):1463\u201376. doi: 10.1517\/14656566.6.9.1463 .","journal-title":"Expert Opin Pharmacother"}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-017-0636-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T17:08:34Z","timestamp":1589821714000},"score":1,"resource":{"primary":{"URL":"https:\/\/systematicreviewsjournal.biomedcentral.com\/articles\/10.1186\/s13643-017-0636-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["636"],"URL":"https:\/\/doi.org\/10.1186\/s13643-017-0636-y","relation":{},"ISSN":["2046-4053"],"issn-type":[{"value":"2046-4053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12]]},"article-number":"244"}}